June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Podcasts|December 23, 2020
Comparing micro-bypass implant + phaco vs phaco in POAG
Author(s)David Hutton, Alex Delaney-Gesing
Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.
Advertisement
During AAO 2020, Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.
Advertisement
Related to this article
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Alvotech files first known aflibercept 8 mg biosimilar with EMA
2
AAO 2026: How to become an ocular pain detective in dry eye
3
AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON results
4
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
5